Described are methods and pharmaceutical compositions for treating or preventing bacterial infections and other disease and conditions caused by bacterial imbalance or mediated via human microbiota. For example, described are pharmaceutical compositions comprising sub-minimum inhibitory concentrations of reactive oxygen species sufficient for arresting virulence through inhibition of quorum sensing, thereby modifying microbiota to a healthy state
